(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.97%) $83.04
(-1.16%) $1.619
(-0.26%) $2 341.20
(-0.05%) $27.52
(0.50%) $926.70
(-0.15%) $0.933
(-0.15%) $11.01
(-0.24%) $0.798
(0.00%) $92.17
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 7.20%
-0.07% $ 0.682
Live Chart Being Loaded With Signals
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults...
Stats | |
---|---|
Dzisiejszy wolumen | 41 555.00 |
Średni wolumen | 54 452.00 |
Kapitalizacja rynkowa | 131.23M |
EPS | $0 ( 2024-03-07 ) |
Następna data zysków | ( $-0.220 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.790 |
ATR14 | $0.0100 (1.47%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-08 | Tasse Daniel | Buy | 17 094 | Ordinary Shares |
2024-02-06 | Ndu Adora | Buy | 1 825 | Ordinary Shares |
2023-11-22 | Mohideen Pharis | Sell | 2 245 | Ordinary Shares |
2023-11-20 | Boucinha Virginie | Buy | 113 000 | Employee Stock Option (right to buy) |
2023-11-20 | Boucinha Virginie | Buy | 19 000 | Ordinary Shares |
INSIDER POWER |
---|
99.85 |
Last 57 transactions |
Buy: 29 162 445 | Sell: 1 080 406 |
DBV Technologies S.A. Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
PLPC | 0.902 |
GPOR | 0.891 |
MCAA | 0.89 |
ENTF | 0.887 |
MLAI | 0.886 |
PPYA | 0.884 |
AHRN | 0.883 |
FRSG | 0.882 |
ACQR | 0.88 |
FTAA | 0.88 |
10 Najbardziej negatywne korelacje | |
---|---|
INCY | -0.916 |
SRTS | -0.904 |
FARO | -0.897 |
BXRX | -0.896 |
NWL | -0.895 |
CDXS | -0.892 |
NURO | -0.888 |
AYTU | -0.888 |
RCKY | -0.886 |
SBAC | -0.88 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
DBV Technologies S.A. Finanse
Annual | 2023 |
Przychody: | $15.73M |
Zysk brutto: | $20.23M (128.59 %) |
EPS: | $-0.380 |
FY | 2023 |
Przychody: | $15.73M |
Zysk brutto: | $20.23M (128.59 %) |
EPS: | $-0.380 |
FY | 2022 |
Przychody: | $4.80M |
Zysk brutto: | $-16.53M (-344.46 %) |
EPS: | $-0.620 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.890 |
Financial Reports:
No articles found.
DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej